Walder Wyss advised CABB Group on its issuance of EUR 625 million 8.00% senior secured notes due 2031. CABB Group, which is owned by Permira funds, is a Crop Science contract development and manufacturing organization (CDMO), supplying customised
Tags :Tervel Stoyanov
Walder Wyss advised funds managed by Pharmakon Advisors — an investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds — in connection with their role as investors in
Walder Wyss advised Zurich-based Beekeeper in connection with the closing of a growth and working capital financing from HSBC Innovation Bank Limited. The company Founded in 2012 by Cristian Grossmann, Andreas Slotosch, Daniel Sztutwojner, and Flavio
Walder Wyss advised the funds managed by OrbiMed Advisors LLC on secure financing to vVARDIS group, a Swiss developer and manufacturer of dental products. The context Founded by Dr. Haley Abivardi and Dr. Goly Abivardi,
Walder Wyss advised the funds managed by Perceptive Advisor, a privately owned hedge fund sponsor investing in biotechnology and life sciences sectors, on the secured term loan financing for up USD 50,000,000 granted to Sophia Genetics,
Walder Wyss advised the funds managed by Pharmakon Advisors, an investor in non-dilutive debt for the life sciences industry and investment manager of the BioPharma credit funds. Banking and finance counsel Tervel Stoyanov (pictured left)
Solör Bioenergy Group´s main shareholder, Nordic Infrastructure AG, successfully completed the first close of €215m Green Mezzanine Debt Facility. Solör Bioenergy Group is a leading energy company in the Nordics for wood-based
Walder Wyss acted as legal counsel to Ionisos SAS on its recent acquisition of an E-beam sterilization and cross-linking facility from Studer Cables. Studer Cables, a prominent technology company specializing in high-performance cables for various
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP, in connection with the closing of the term loan financing of Reata Pharmaceuticals for up to USD 275 million. Reata Pharmaceuticals, is a global biopharmaceutical
The CABB Group has successfully concluded its refinancing round. New bonds with a total volume of EUR 670 million and terms until 2028 were successfully placed with institutional investors. The issue comprises two tranches: EUR 420 million with
